1.
RSC Adv
; 6(16): 12959-12963, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26998252
RESUMO
Rifampicin (RIF) is a benchmark drug for treatment of tuberculosis, but poor bioavailability, prolonged treatment, and pill burden have been linked to therapeutic failure and the development of multidrug resistant strains. To overcome these limitations, this study investigated a method of rifampicin nanoencapsulation and aerosol delivery using a commercial, hand-held nebulizer modified with a nitrogen stream.